Evidence map›Paper›PMID 30369807›Full record

ArticleEuropean journal of dentistry

Cytotoxicity evaluation of a new ozonized olive oil.

Marco Colombo, Matteo Ceci, Eleonora Felisa, Claudio Poggio, Giampiero Pietrocola

Open access · hybridAbstract read
In one paragraph

Article in European journal of dentistry. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Evaluation of the Sensitivity of SelectedMedicina (Kaunas, Lithuania) · 2022
    Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Marco ColomboDepartment of Clinical-Surgical, Diagnostic and Pediatric Sciences, Section of Dentistry, University of Pavia, Pavia, Italy.
Matteo CeciDepartment of Clinical-Surgical, Diagnostic and Pediatric Sciences, Section of Dentistry, University of Pavia, Pavia, Italy.
Eleonora FelisaDepartment of Clinical-Surgical, Diagnostic and Pediatric Sciences, Section of Dentistry, University of Pavia, Pavia, Italy.
Claudio PoggioDepartment of Clinical-Surgical, Diagnostic and Pediatric Sciences, Section of Dentistry, University of Pavia, Pavia, Italy.
Giampiero PietrocolaDepartement of Molecular Medicine, Unit of Biochemistry, University of Pavia, Pavia, Italy.
University of Pavia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe cytocompatibility of a new ozonized olive oil toward immortalized human gingival fibroblasts (HGFs) was evaluated and compared with two common antimicrobial agents based on chlorhexidine digluconate (CHX). MATERIALS AND

methodsThe cytocompatibility of the samples was tested on immortalized HGF-1 cells by 3-(4, 5-dimethyl thiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay. The cells were incubated for 2 or 24 h with increasing dilution of ozonized olive oil or CHX agents. The percentage of viable cells was calculated relative to control cells set to 100%.

resultsThe ozonized olive oil is cytocompatible, and the viability values of the cells treated for 2 or 24 h with increasing concentrations of ozonized olive oil were significantly higher (

conclusionsThe present data demonstrate that due to its cytocompatibility, the new ozonized olive oil could be considered an alternative antibacterial agent.

Indexed as

3-(4, 5-dimethyl thiazolyl-2)-2, 5-diphenyltetrazolium bromide testcytotoxicitygingival fibroblastozonized olive oil

Identifiers

PMID30369807
PMCPMC6178687
OpenAlexW2895112430

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.